Websites
Enric Domingo
BSc, MSc, PhD
Postdoc in bioinformatics
RESEARCH SUMMARY
My work has always been focused on colorectal cancer and translational research, with a slow transition from the wet lab to computer-based research. My main goal is the identification of biomarkers that could be implemented clinically to improve healthcare. Accordingly, along my career I have identified highly relevant biomarkers in colorectal cancer (eg BRAF mutation to exclude germline predisposition; POLE mutation for good prognosis; PIK3CA mutation for benefit with aspirin).
My research is strongly focused on molecular profiling of human tumours. To that end, I apply a wide range of bioinformatical tools to multi-omic data (eg DNA sequencing, DNA methylation, RNA expression, protein expression) from highly selected patients of clinical trials or hospital-based cohorts. Several of them are from the S:CORT programme, a stratified medicine consortium looking for biomarkers of response to oxaliplatin, radiotherapy, prognosis and novel biological therapies. I lead my own research lines (eg germline variants, some specific biomarker candidates, site of metastasis) and have tight collaborations with the whole S:CORT team and other researchers nationally and internationally.
BIOGRAPHY
I received a BSc in Biology (Autonomous University of Barcelona) and a MSc and PhD in Genetics (Vall d’Hebron Research Institute, Barcelona). I have also been a visiting fellow in INSERM (Paris) and postdoc in the London Research Institute (now The Francis Crick Institute) and the Wellcome Trust Centre for Human Genetics (Oxford).
Key publications
-
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
Journal article
Domingo E. et al, (2018), Lancet Gastroenterol Hepatol, 3, 635 - 643
-
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Journal article
Domingo E. et al, (2016), Lancet Gastroenterol Hepatol, 1, 207 - 216
-
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Journal article
Domingo E. et al, (2013), J Clin Oncol, 31, 4297 - 4305
-
Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
Journal article
Domingo E. et al, (2013), J Pathol, 229, 441 - 448
-
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.
Journal article
Domingo E. et al, (2004), J Med Genet, 41, 664 - 668
Recent publications
-
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
Journal article
Sirinukunwattana K. et al, (2021), Gut, 70, 544 - 554
-
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Journal article
Malla SB. et al, (2021), Clin Cancer Res, 27, 288 - 300
-
Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification.
Journal article
Kleeman SO. et al, (2020), Gut, 69, 1092 - 1103
-
The interleukin 22 pathway interacts with mutant KRAS to promote poor prognosis in colon cancer.
Journal article
McCuaig S. et al, (2020), Clin Cancer Res
-
TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts.
Journal article
Fielden J. et al, (2020), Nat Commun, 11